Warning: The NCBI web site requires JavaScript to function. more...
Over-expression of Skp2 is associated with resistance to preoperative doxorubicin-based chemotherapy in primary breast cancer.
Davidovich S, Ben-Izhak O, Shapira M, Futerman B, Hershko DD.
Breast Cancer Res. 2008;10(4):R63. Epub 2008 Jul 21.
Related citations
Reduced expression of p27Kip1 protein is associated with poor clinical outcome of breast cancer patients treated with systemic chemotherapy and is linked to cell proliferation and differentiation.
Han S, Park K, Kim HY, Lee MS, Kim HJ, Kim YD.
Breast Cancer Res Treat. 1999 May;55(2):161-7.
Differential effects of doxorubicin treatment on cell cycle arrest and Skp2 expression in breast cancer cells.
Bar-On O, Shapira M, Hershko DD.
Anticancer Drugs. 2007 Nov;18(10):1113-21.
The expression of the ubiquitin ligase subunit Cks1 in human breast cancer.
Slotky M, Shapira M, Ben-Izhak O, Linn S, Futerman B, Tsalic M, Hershko DD.
Breast Cancer Res. 2005;7(5):R737-44. Epub 2005 Jul 19.
p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer.
Ravaioli A, Monti F, Regan MM, Maffini F, Mastropasqua MG, Spataro V, Castiglione-Gertsch M, Panzini I, Gianni L, Goldhirsch A, Coates A, Price KN, Gusterson BA, Viale G; International Breast Cancer Study Group.
Ann Oncol. 2008 Apr;19(4):660-8. Epub 2008 Feb 13.
Significance of skp2 expression in primary breast cancer.
Sonoda H, Inoue H, Ogawa K, Utsunomiya T, Masuda TA, Mori M.
Clin Cancer Res. 2006 Feb 15;12(4):1215-20.
Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab.
Seki R, Ohshima K, Fujisaki T, Uike N, Kawano F, Gondo H, Makino S, Eto T, Moriuchi Y, Taguchi F, Kamimura T, Tsuda H, Shimoda K, Okamura T.
Ann Oncol. 2010 Apr;21(4):833-41. Epub 2009 Nov 4.
EGCG stabilizes p27kip1 in E2-stimulated MCF-7 cells through down-regulation of the Skp2 protein.
Huang HC, Way TD, Lin CL, Lin JK.
Endocrinology. 2008 Dec;149(12):5972-83. Epub 2008 Aug 21.
Drug resistance in chemotherapy for breast cancer.
Saeki T, Tsuruo T, Sato W, Nishikawsa K.
Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:84-9.
Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy.
Pohl G, Rudas M, Taucher S, Stranzl T, Steger GG, Jakesz R, Pirker R, Filipits M.
Breast Cancer Res Treat. 2003 Mar;78(1):97-103.
Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
Schneider J, Lucas R, Sánchez J, Ruibal A, Tejerina A, Martín M.
Anticancer Res. 2000 Nov-Dec;20(6B):4373-7.
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.
Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
BMC Cancer. 2007 Nov 1;7:203.
HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.
Tiezzi DG, Andrade JM, Ribeiro-Silva A, Zola FE, Marana HR, Tiezzi MG.
BMC Cancer. 2007 Feb 26;7:36.
High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin.
Pohl G, Rudas M, Dietze O, Lax S, Markis E, Pirker R, Zielinski CC, Hausmaninger H, Kubista E, Samonigg H, Jakesz R, Filipits M.
J Clin Oncol. 2003 Oct 1;21(19):3594-600.
Elevated S-phase kinase-associated protein 2 protein expression in acute myelogenous leukemia: its association with constitutive phosphorylation of phosphatase and tensin homologue protein and poor prognosis.
Min YH, Cheong JW, Lee MH, Kim JY, Lee ST, Hahn JS, Ko YW.
Clin Cancer Res. 2004 Aug 1;10(15):5123-30.
Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarcomas.
Huang HY, Kang HY, Li CF, Eng HL, Chou SC, Lin CN, Hsiung CY.
Clin Cancer Res. 2006 Jan 15;12(2):487-98.
Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer.
Lee J, Im YH, Lee SH, Cho EY, Choi YL, Ko YH, Kim JH, Nam SJ, Kim HJ, Ahn JS, Park YS, Lim HY, Han BK, Yang JH.
Cancer Chemother Pharmacol. 2008 Apr;61(4):569-77. Epub 2007 May 17.
Prognostic impact of Skp2 and p27 in human breast cancer.
Traub F, Mengel M, Lück HJ, Kreipe HH, von Wasielewski R.
Breast Cancer Res Treat. 2006 Sep;99(2):185-91. Epub 2006 Apr 25.
p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy.
Porter PL, Barlow WE, Yeh IT, Lin MG, Yuan XP, Donato E, Sledge GW, Shapiro CL, Ingle JN, Haskell CM, Albain KS, Roberts JM, Livingston RB, Hayes DF.
J Natl Cancer Inst. 2006 Dec 6;98(23):1723-31.
The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype.
Voduc D, Nielsen TO, Cheang MC, Foulkes WD.
Hum Pathol. 2008 Oct;39(10):1431-7. Epub 2008 Jul 11.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on